The challenge of developing robust drugs to overcome resistance

Drug Discovery Today

Volumn 16, Issue 17-18, 2011, Pages 755-761

  Anderson, Amy C ^a,b   Pollastri, Michael P ^a,c   Schiffer, Celia A ^a,d   Peet, Norton P ^a,e  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e MICROBIOTIX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CIPROFLOXACIN; DASATINIB; DIHYDROFOLATE REDUCTASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GROWTH FACTOR RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; ICLAPRIM; IMATINIB; MIDOSTAURIN; MONOCLONAL ANTIBODY; MOXIFLOXACIN; NALIDIXIC ACID; NERATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; QUINOLONE DERIVATIVE; SORAFENIB; SULFAMETHOXAZOLE; TRIMETHOPRIM; UNINDEXED DRUG;

CLINICAL EFFECTIVENESS; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPEREOSINOPHILIC SYNDROME; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

EID: 80052845491     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.07.001     Document Type: Short Survey

References (89)

1. N.P. Peet Drug resistance: a growing problem Drug Discov. Today 15 2010 583 586
2. E. Lefebvre, and C.A. Schiffer Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir AIDS Rev. 10 2008 131 142
3. M.N. Nalam, and C.A. Schiffer New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors Curr. Opin. HIV AIDS 3 2008 642 646
4. R. Oerlemans Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein Blood 112 2008 2489 2499
5. S. Lu Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line Exp. Hematol. 36 2008 1278 1284
6. T. Kute Development of Herceptin resistance in breast cancer cells Cytometry A 57 2004 86 93 (Pubitemid 38197598)
7. N.P. Shah Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis Cancer Cell 14 2008 485 493
8. M. Huse, and J. Kuriyan The conformational plasticity of protein kinases Cell 109 2002 275 282 (Pubitemid 34606870)
9. Y. Liu, and N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2 2006 358 364 (Pubitemid 43936934)
10. S.R. Hubbard Crystal structure of the tyrosine kinase domain of the human insulin receptor Nature 372 1994 746 754
11. E.A. Nigg Mitotic kinases as regulators of cell division and its checkpoints Nat. Rev. Mol. Cell Biol. 2 2001 21 32 (Pubitemid 33676958)
12. B.J. Druker Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N. Engl. J. Med. 344 2001 1038 1042 (Pubitemid 32267973)
13. M.E. Gorre Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880 (Pubitemid 32743979)
14. C.L. Sawyers Even better kinase inhibitors for chronic myeloid leukemia N. Engl. J. Med. 362 2010 2314 2315
15. A. Quintas-Cardama Flying under the radar: the new wave of BCR-ABL inhibitors Nat. Rev. Drug Discov. 6 2007 834 848 (Pubitemid 47500507)
16. D. Patel BCR ABL kinase inhibitors for cancer therapy Int. J. Pharm. Sci. Drug Res. 2 2010 80 90
17. H. Kantarjian Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N. Engl. J. Med. 354 2006 2542 2551 (Pubitemid 43882350)
18. M. Talpaz Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N. Engl. J. Med. 354 2006 2531 2541 (Pubitemid 43882349)
19. L.J. Lombardo Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2- hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5- carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J. Med. Chem. 47 2004 6658 6661 (Pubitemid 40053752)
20. E. Weisberg Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 2005 129 141 (Pubitemid 40248339)
21. N.P. Shah Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401 (Pubitemid 38938156)
22. M. Stanglmaier The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains Leukemia 17 2003 283 289 (Pubitemid 36266903)
23. L. Coussens Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene Science 230 1985 1132 1139 (Pubitemid 16169997)
24. N. Hynes, and H. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat. Rev. Cancer 5 2005 341 354 (Pubitemid 40637826)
25. C. King Amplification of a novel v-erbB-related gene in a human mammary carcinoma Science 229 1985 974 976 (Pubitemid 16248488)
26. C. Lin Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells Science 224 1984 843 848 (Pubitemid 14102458)
27. M. Olayioye The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J. 19 2000 3159 3167 (Pubitemid 30428195)
28. A. Schechter The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor Science 229 1985 976 978 (Pubitemid 16248489)
29. J. Schlessinger Common and distinct elements in cellular signaling via EGF and FGF receptors Science 306 2004 1506 1507 (Pubitemid 39564935)
30. Y. Yarden, and M. Sliwkowski Untangling the ErbB signaling network Nat. Rev. Mol. Cell Biol. 2 2001 127 137
31. N. Thatcher Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537 (Pubitemid 41540110)
32. J. Stamos Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 277 2002 46265 46272 (Pubitemid 35417619)
33. E. Kwak Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc. Natl. Acad. Sci. 102 2005 7665 7670 (Pubitemid 40741028)
34. W. Pao Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2 2005 e73
35. M. Gorre Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880 (Pubitemid 32743979)
36. J. Cools A tyrosine kinsae created by fusion of the PDGFRα and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome N. Engl. J. Med. 348 2003 1201 1214 (Pubitemid 36359296)
37. E. Tamborini A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient Gastroenterology 127 2004 294 299 (Pubitemid 38962296)
38. S. Kobayashi EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 352 2005 786 792 (Pubitemid 40271173)
39. C. Yun The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. 105 2008 2070 2075 (Pubitemid 351439466)
40. N. Godin-Heymann The T790M gatekeeper mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor Mol. Cancer Ther. 7 2008 874 879 (Pubitemid 351551040)
41. J. Singh Targeted covalent drugs of the kinase family Curr. Opin. Chem. Biol. 14 2010 475 480
42. M. Azam Activation of tyrosine kinases by mutation of the gatekeeper threonine Nat. Struct. Mol. Biol. 15 2008 1109 1118
43. C. Nishioka Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo Blood 111 2008 5086 5092
44. S. Verstovsek Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFRα-expressing cells Leuk. Res. 30 2006 1499 1505 (Pubitemid 44573482)
45. J. Pan The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGRFα-expressing cells through caspase-3-mediated cleavage of Mcl-1 Leukemia 21 2007 1395 1404 (Pubitemid 46965280)
46. E. Lierman FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib Leukemia 23 2009 845 851
47. E. Weisberg Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRa, Kit, and Src kinases: novel type II inhibitors of gatekeeper mutants Blood 115 2010 4206 4216
48. G. Dale A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance J. Mol. Biol. 266 1997 23 30 (Pubitemid 27170515)
49. R.H. Drew Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections Pharmacotherapy 27 2007 227 249 (Pubitemid 46214584)
50. R.A. Proctor Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection Clin. Infect. Dis. 46 2008 584 593 (Pubitemid 351263501)
51. K. Frey Crystal structures of wild-type and mutant methicillin-resistant Staphylococcus aureus dihydrofolate reductase reveal an alternative conformation of NADPH that may be linked to trimethoprim resistance J. Mol. Biol. 387 2009 1298 1308
52. K. Frey Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductase J. Struct. Biol. 170 2010 93 97
53. P. Schneider Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria Bioorg. Med. Chem. Lett. 13 2003 4217 4221 (Pubitemid 37410316)
54. C. Oefner Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity J. Antimicrob. Chemother. 63 2009 687 698
55. F. Blanche Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases Antimicrob. Agents Chemother. 40 1996 2714 2720 (Pubitemid 26404331)
56. V.F. Holmes, and N.R. Cozzarelli Closing the ring: links between SMC proteins and chromosome partitioning, condensation, and supercoiling Proc. Natl. Acad. Sci. U.S.A. 97 2000 1322 1324 (Pubitemid 30118433)
57. J.A. Sawitzke, and S. Austin Suppression of chromosome segregation defects of Escherichia coli muk mutants by mutations in topoisomerase I Proc. Natl. Acad. Sci. U.S.A. 97 2000 1671 1676 (Pubitemid 30118501)
58. G.A. Jacoby Mechanisms of resistance to quinolones Clin. Infect. Dis. 41 Suppl. 2 2005 120 126
59. I. Laponogov Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases Nat. Struct. Mol. Biol. 16 2009 667 669
60. K. Drlica Quinolones: action and resistance updated Curr. Top. Med. Chem. 9 2009 981 998
61. J. Vila Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs Antimicrob. Agents Chemother. 38 1994 2477 2479 (Pubitemid 24304253)
62. B.D. Bax Type IIA topoisomerase inhibition by a new class of antibacterial agents Nature 466 2010 935 940
63. A. Maxwell, and D.M. Lawson The ATP-binding site of type II topoisomerases as a target for antibacterial drugs Curr. Top. Med. Chem. 3 2003 283 303
64. J.A. Ali The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs Biochemistry 32 1993 2717 2724 (Pubitemid 23090662)
65. S.P. East DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity Bioorg. Med. Chem. Lett. 19 2009 894 899
66. S.C. Annedi, and L.P. Kotra RU-79115 (Aventis Pharma) Curr. Opin. Invest. Drugs 2 2001 752 754
67. P. Angehrn New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine J. Med. Chem. 47 2004 1487 1513 (Pubitemid 38327474)
68. M. Oblak Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents Curr. Med. Chem. 14 2007 2033 2047 (Pubitemid 47578161)
69. J.T. Starr 5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV Bioorg. Med. Chem. Lett. 19 2009 5302 5306
70. A. Tanitame Synthesis and antibacterial activity of a novel series of DNA gyrase inhibitors: 5-[(E)-2-arylvinyl]pyrazoles Bioorg. Med. Chem. Lett. 15 2005 4299 4303 (Pubitemid 41188007)
71. N.E. Kohl Active human immunodeficiency virus protease is required for viral infectivity Proc. Natl. Acad. Sci. U.S.A. 85 1988 4686 4690
72. R.M. Gulick 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine Ann. Intern. Med. 133 2000 35 39 (Pubitemid 30432542)
73. J.A. Bartlett Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults AIDS 15 2001 1369 1377 (Pubitemid 32663904)
74. Stanford HIV Drug Resistance Database. Available at http://hivdb. Stanford.edu
75. T.D. Wu Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments J. Virol. 77 2003 4836 4847 (Pubitemid 36402833)
76. N.M. King Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor J. Virol. 78 2004 12012 12021 (Pubitemid 39390785)
77. N.M. King Combating susceptibility to drug resistance: lessons from HIV-1 protease Chem. Biol. 11 2004 1333 1338 (Pubitemid 39351371)
78. ®TYPE resistance analysis, including clinical cut-offs, for TMC114 Antivir. Ther. 11 2006 S180
79. S. Chellappan Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis Chem. Biol. Drug Des. 69 2007 298 313 (Pubitemid 46817456)
80. M.N. Nalam Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance J. Virol. 84 2008 5368 5378
81. A. Ali Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands J. Med. Chem. 49 2006 7342 7356 (Pubitemid 44913395)
82. S. Chellappan Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease Proteins 68 2007 561 567 (Pubitemid 46981948)
83. M.D. Altman HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants J. Am. Chem. Soc. 130 2008 6099 6113 (Pubitemid 351657286)
84. M.N.L. Nalam Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance J. Virol. 84 2010 5368 5378
85. World Health Organization Initiative for Vaccine Research. Hepatitis C. Available at http://www.who.int/vaccine-research/diseases/viral-cancers/en/ index2.html
86. K.P. Romano Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding Proc. Natl. Acad. Sci. U.S.A. 2010 10.1073/pnas.1006370107
87. M.D. Altman Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease Proteins 70 2008 678 694 (Pubitemid 351161930)
88. M. Prabu-Jeyabalan Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease Antimicrob. Agents Chemother. 50 2006 1518 1521
89. A.B. Benowitz Antibacterial drug discovery in the age of resistance Microbe 5 2010 390 396